ClinicalTrials.gg
CompletedNCT02648217Updated Sep 11, 2018Results posted

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

A Phase 3 interventional study of insulin degludec/insulin aspart and biphasic insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-11.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
45th of 70
263 · median 384
Started
2016
with 5 others
Phase 3
49 of 70
2 open now
Registered
47th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 45th largest by enrollment, is one of 6 that started in 2016, is one of 49 in phase 3, and was the 47th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus before, during and after Ramadan.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 263 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age at least 18 years at the time of signing . Algeria: Male or female, age at least 19 years at the time of signing informed consent
  • Subjects diagnosed (clinically) with type 2 diabetes mellitus prior to day of screening (Visit 1)
  • Treated with any pre-mix/self-mix or basal insulin regimen for at least 90 days prior to the day of screening (Visit 1)
  • Subjects not on any OAD(s) (oral anti-diabetic drug) prior to trial participation OR subjects on fixed daily dose(s) of OAD(s) for at least 90 days prior to screening (Visit 1). The OAD(s) include any of the following anti-diabetic drug(s)/regimen: Biguanides (metformin equal to or above 1500 mg or maximum tolerated dose documented in the subject medical record) Insulin secretagogues (sulfonylureas (SU) and glinides), Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), a-glucosidase inhibitors, Sodium-glucose co-transporter 2- inhibitors (SGLT2 Inhibitors ) (above or equal to half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record)
  • 7.0%-10.0% (53-86 mmol/mol) (both inclusive, by central laboratory analysis)
  • Intention to fast (daytime, i.e., between dawn and sunset) during Ramadan after receiving medical counselling regarding the risk of fasting
  • Willing to give blood during Ramadan

Exclusion criteria

Exclusion Criteria:

  • Any for successful and sustained fasting from a medical perspective at the discretion of the investigator (such as acute illness, severe hypoglycaemia within 90 days prior to screening (Visit 1), hypoglycaemia unawareness, ketoacidosis within 90 days prior to screening (Visit), hyperosmolar hyperglycaemic coma within 90 days prior to screening (Visit 1), subjects performing intense physical labour)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    IDegAsp U100 BID

    Drug: insulin degludec/insulin aspart

  • Active comparator
    BIAsp U100 BID

    Drug: biphasic insulin aspart

Interventions

  • Druginsulin degludec/insulin aspart

    Drug pages: Insulin degludec · Insulin Aspart

    Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.

  • Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.

07

What researchers measure

Primary outcomes

  1. Change in HbA1c (%) (Glycosylated Haemoglobin)

    Mean change in HbA1c was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).

    Time frame: From week 0 to end of Ramadan (day 29 of Ramadan)

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG)

    Mean change in FPG was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).

    Time frame: From week 0 to end of Ramadan (day 29 of Ramadan)

  2. Change in Fructosamine

    Mean change in fructosamine was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).

    Time frame: From week 0 to end of Ramadan (day 29 of Ramadan)

  3. Number of Subjects Who Achieve HbA1c Below 7% (53 mmol/Mol (American Diabetes Association (ADA) Target )

    Number of subjects who achieved HbA1c below 7% (53 mmol/mol; ADA target) at the end of Ramadan (day 29 of Ramadan).

    Time frame: End of Ramadan (day 29 of Ramadan)

  4. Number of Subjects Who Achieve FPG Below or Equal to 7.2 mmol/L (ADA Target)

    Number of subjects who achieved FPG \<=7.2 mmol/L at the end of Ramadan (day 29 of Ramadan). The above written (in the endpoint title) 'ADA target' is not applicable for FPG.

    Time frame: End of Ramadan (day 29 of Ramadan)

  5. Number of Treatment Emergent Hypoglycaemic Episodes Both According to the Novo Nordisk Definition for Hypoglycaemic Episodes (Severe or BG Hypoglycaemia) as Well as According to the ADA definition1 Confirmed Symptomatic

    Treatment-emergent hypoglycaemic episodes: If the onset of the episode occurred on or after the first day of investigational medicinal product (IMP; IDegAsp/BIAsp 30) administration, and no later than 1 day after the last day on IMP, before switching to or being treated with another insulin product. The above mentioned definitions (in endpoint title) should read as the following: Novo Nordisk definition; severe or blood glucose (BG) confirmed symptomatic hypoglycaemia: An episode that was severe according to ADA classification or BG confirmed by a plasma glucose (PG) value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. American Diabetes Association (ADA) definition; documented symptomatic hypoglycaemia: An episode, during which typical symptoms of hypoglycaemia were accompanied by a measured PG concentration ≤3.9 mmol/L (70 mg/dL). Due to character limitation, severe hypoglycaemia as per ADA classification is not defined here; see next outcome measure.

    Time frame: From week 0 to 4 weeks post Ramadan

  6. Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes, which occurred between 00:01 and 05:59 both inclusive. Novo Nordisk definition; severe or blood glucose (BG) confirmed symptomatic hypoglycaemia: An episode that was severe according to ADA classification or BG confirmed by a plasma glucose (PG) value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

    Time frame: From week 0 to 4 weeks post Ramadan

08

Results

Posted Sep 11, 2018

Participant flow

The trial was conducted at 27 sites in 5 countries as follows: Algeria: 4 sites; India: 7 sites; Lebanon: 4 sites; Malaysia: 3 sites; South Africa: 9 sites.

Participant flow — Overall Study
MilestoneInsulin Degludec/Insulin AspartBiphasic Insulin Aspart 30
Started131132
Exposed130132
Completed121127
Not completed105
Withdrew: Adverse event01
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject43
Withdrew: Unclassified50

Outcome measures

PrimaryChange in HbA1c (%) (Glycosylated Haemoglobin)

Mean change in HbA1c was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).

Time frame:
From week 0 to end of Ramadan (day 29 of Ramadan)
Reported as:
Least squares mean · Percentage (%) of HbA1c
Change in HbA1c (%) (Glycosylated Haemoglobin)
Percentage (%) of HbA1cInsulin Degludec/Insulin AspartBiphasic Insulin Aspart 30
Change in HbA1c (%) (Glycosylated Haemoglobin)-1.11 ± 0.13-1.13 ± 0.13
Statistical analysis
  • Insulin Degludec/Insulin Aspart vs Biphasic Insulin Aspart 30 · Mixed model for repeated measurements · p = 0.8426 · Treatment contrast: 0.02 · 95% CI -0.20 to 0.24
SecondaryChange in Fasting Plasma Glucose (FPG)

Mean change in FPG was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).

Time frame:
From week 0 to end of Ramadan (day 29 of Ramadan)
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG)
mmol/LInsulin Degludec/Insulin AspartBiphasic Insulin Aspart 30
Change in Fasting Plasma Glucose (FPG)-2.0 ± 12.4-4.4 ± 18.0
SecondaryChange in Fructosamine

Mean change in fructosamine was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).

Time frame:
From week 0 to end of Ramadan (day 29 of Ramadan)
Reported as:
Mean · mmol/L
Change in Fructosamine
mmol/LInsulin Degludec/Insulin AspartBiphasic Insulin Aspart 30
Change in Fructosamine-0.035 ± 0.051-0.035 ± 0.048
SecondaryNumber of Subjects Who Achieve HbA1c Below 7% (53 mmol/Mol (American Diabetes Association (ADA) Target )

Number of subjects who achieved HbA1c below 7% (53 mmol/mol; ADA target) at the end of Ramadan (day 29 of Ramadan).

Time frame:
End of Ramadan (day 29 of Ramadan)
Reported as:
Number · Number of subjects
Number of Subjects Who Achieve HbA1c Below 7% (53 mmol/Mol (American Diabetes Association (ADA) Target )
Number of subjectsInsulin Degludec/Insulin AspartBiphasic Insulin Aspart 30
Subjects with HbA1c <7.0% (Yes)3842
Subjects with HbA1c <7.0% (No)8381
SecondaryNumber of Subjects Who Achieve FPG Below or Equal to 7.2 mmol/L (ADA Target)

Number of subjects who achieved FPG \<=7.2 mmol/L at the end of Ramadan (day 29 of Ramadan). The above written (in the endpoint title) 'ADA target' is not applicable for FPG.

Time frame:
End of Ramadan (day 29 of Ramadan)
Reported as:
Number · Number of subjects.
Number of Subjects Who Achieve FPG Below or Equal to 7.2 mmol/L (ADA Target)
Number of subjects.Insulin Degludec/Insulin AspartBiphasic Insulin Aspart 30
Subjects with FPG <=7.2 mmol/L (Yes)6583
Subjects with FPG <=7.2 mmol/L (No)5640
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes Both According to the Novo Nordisk Definition for Hypoglycaemic Episodes (Severe or BG Hypoglycaemia) as Well as According to the ADA definition1 Confirmed Symptomatic

Treatment-emergent hypoglycaemic episodes: If the onset of the episode occurred on or after the first day of investigational medicinal product (IMP; IDegAsp/BIAsp 30) administration, and no later than 1 day after the last day on IMP, before switching to or being treated with another insulin product. The above mentioned definitions (in endpoint title) should read as the following: Novo Nordisk definition; severe or blood glucose (BG) confirmed symptomatic hypoglycaemia: An episode that was severe according to ADA classification or BG confirmed by a plasma glucose (PG) value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. American Diabetes Association (ADA) definition; documented symptomatic hypoglycaemia: An episode, during which typical symptoms of hypoglycaemia were accompanied by a measured PG concentration ≤3.9 mmol/L (70 mg/dL). Due to character limitation, severe hypoglycaemia as per ADA classification is not defined here; see next outcome measure.

Time frame:
From week 0 to 4 weeks post Ramadan
Reported as:
Number · Number of episodes.
Number of Treatment Emergent Hypoglycaemic Episodes Both According to the Novo Nordisk Definition for Hypoglycaemic Episodes (Severe or BG Hypoglycaemia) as Well as According to the ADA definition1 Confirmed Symptomatic
Number of episodes.Insulin Degludec/Insulin AspartBiphasic Insulin Aspart 30
Severe or BG confirmed symptomatic hypoglycaemia93389
Documented symptomatic hypoglycaemia521775
SecondaryNumber of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes, which occurred between 00:01 and 05:59 both inclusive. Novo Nordisk definition; severe or blood glucose (BG) confirmed symptomatic hypoglycaemia: An episode that was severe according to ADA classification or BG confirmed by a plasma glucose (PG) value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Time frame:
From week 0 to 4 weeks post Ramadan
Reported as:
Number · Number of episodes.
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Number of episodes.Insulin Degludec/Insulin AspartBiphasic Insulin Aspart 30
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes18106

Adverse events

Collected over From first day of exposure to randomised treatment (week 0) and no later than seven days after the last day of randomised treatment (i.e., after 16-28 weeks; 8-20 weeks treatment initiation period [pre-Ramadan], 4-week Ramadan treatment period, and 4 week post-Ramadan period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec/Insulin Aspart—5/130 (3.8%)54/130 (41.5%)
Biphasic Insulin Aspart 30—3/132 (2.3%)47/132 (35.6%)
Most frequent serious events
Most frequent serious events
EventInsulin Degludec/Insulin AspartBiphasic Insulin Aspart 30
Myocardial infarctionCardiac disorders2/1300/132
HypoglycaemiaMetabolism and nutrition disorders0/1302/132
Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1300/132
FallInjury, poisoning and procedural complications1/1300/132
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1300/132
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders1/1300/132
PneumoniaInfections and infestations1/1300/132
Spinal osteoarthritisMusculoskeletal and connective tissue disorders1/1300/132
Umbilical herniaGastrointestinal disorders1/1300/132
Accidental overdoseInjury, poisoning and procedural complications0/1301/132
Most frequent other events
Most frequent other events
EventInsulin Degludec/Insulin AspartBiphasic Insulin Aspart 30
Blood glucose decreasedInvestigations46/13040/132
Upper respiratory tract infectionInfections and infestations8/1303/132
PyrexiaGeneral disorders4/1307/132

Baseline characteristics

Baseline results are based on the full analysis set (FAS), which included all randomised subjects.

Age, Continuous
Age, Continuous(Years)Insulin Degludec/Insulin AspartBiphasic Insulin Aspart 30Total
Mean54.9 ± 9.855.3 ± 9.255.1 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Degludec/Insulin AspartBiphasic Insulin Aspart 30Total
Female6780147
Male6452116
Glycated haemoglobin (HbA1c)
Glycated haemoglobin (HbA1c)(Percentage of HbA1c)Insulin Degludec/Insulin AspartBiphasic Insulin Aspart 30Total
Mean8.5 ± 0.98.5 ± 0.98.5 ± 0.9
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)Insulin Degludec/Insulin AspartBiphasic Insulin Aspart 30Total
Mean9.9 ± 10.410.6 ± 16.310.3 ± 13.6
09

Study locations

32 sites
  • Novo Nordisk Investigational Site
    Algiers, Algeria
  • Novo Nordisk Investigational Site
    Oran, 31000, Algeria
  • Novo Nordisk Investigational Site
    Setif, 19000, Algeria
  • Novo Nordisk Investigational Site
    Sidi Bel abbes, 22000, Algeria
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500 001, India
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500058, India
  • Novo Nordisk Investigational Site
    Mysore, Karnataka 570001, India
  • Novo Nordisk Investigational Site
    Kozhikode, Kerala 673017, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400010, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400058, India
  • Novo Nordisk Investigational Site
    Pune, Maharashtra 411001, India
  • Novo Nordisk Investigational Site
    Kolkatta, West Bengal 700073, India
  • Novo Nordisk Investigational Site
    New Delhi, 110001, India
  • Novo Nordisk Investigational Site
    Beirut, Lebanon
  • Novo Nordisk Investigational Site
    Hazmieh, Lebanon
  • Novo Nordisk Investigational Site
    Lebanon - Beirut, 9611, Lebanon
  • Novo Nordisk Investigational Site
    Cheras, 56000, Malaysia
  • Novo Nordisk Investigational Site
    Kota Bharu, Kelantan, 16150, Malaysia
  • Novo Nordisk Investigational Site
    Seremban, Negeri Sembilan, 70400, Malaysia
  • Novo Nordisk Investigational Site
    Benoni, Gauteng 1501, South Africa
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 1812, South Africa
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 1827, South Africa
  • Novo Nordisk Investigational Site
    Lenasia, Gauteng 1827, South Africa
  • Novo Nordisk Investigational Site
    Pretoria, Gauteng 0181, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4091, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4092, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4450, South Africa
  • Novo Nordisk Investigational Site
    Cape Town, Western Cape 7925, South Africa
  • Novo Nordisk Investigational Site
    Ajman, 21499, United Arab Emirates
  • Novo Nordisk Investigational Site
    Ajman, 4184, United Arab Emirates
  • Novo Nordisk Investigational Site
    Dubai, 7272, United Arab Emirates
  • Novo Nordisk Investigational Site
    Umm Al Quwain, 24, United Arab Emirates
10

References and documents

Publications

  • Hassanein M, Echtay AS, Malek R, Omar M, Shaikh SS, Ekelund M, Kaplan K, Kamaruddin NA. Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan. Diabetes Res Clin Pract. 2018 Jan;135:218-226. doi: 10.1016/j.diabres.2017.11.027. Epub 2017 Nov 26. PubMed 29183844 ↗
  • Yang W, Akhtar S, Franek E, Haluzik M, Hirose T, Kalyanam B, Kar S, Wu T, Gogas Yavuz D, Unnikrishnan AG. Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp. Diabetes Ther. 2022 Feb;13(2):311-323. doi: 10.1007/s13300-021-01196-7. Epub 2022 Jan 19. PubMed 35044568 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Sep 2016, 8 months.

Results were first posted in Sep 2018, 2 years after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 8 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2016
First posted
Jan 6, 2016
StartActual
Jan 4, 2016
Primary completionActual
Sep 4, 2016
CompletionActual
Sep 5, 2016
Results first posted
Sep 11, 2018
Last update
Sep 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02648217
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 6, 2016
Start date
Jan 4, 2016
Primary completion
Sep 4, 2016
Completion
Sep 5, 2016
Results posted
Sep 11, 2018
Last update
Sep 11, 2018

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart

Start the discussion